
WAY Stock Forecast & Price Target
WAY Analyst Ratings
Bulls say
Waystar Holding is expected to continue its strong growth in the healthcare industry, driven by its innovative AI and revenue cycle technology solutions, cross-selling opportunities from its recent acquisition of Iodine, and strong market presence. Although there are potential challenges and concerns, including high debt and ownership by PE/VC firms, Waystar's strong performance and guidance, as well as the projected value of $33 per share, make it a top choice for hospital executives seeking efficient and effective solutions.
Bears say
Waystar Holding is facing challenges with retaining and adding new members in a highly competitive and rapidly evolving market. Despite its differentiated technology and potential for time and cost savings for healthcare providers, the company's valuation is trading at a discount to its peers. The latest model update shows lowered revenue and EBITDA estimates, resulting in a lowered price target, but we believe near-term drivers and potential for cross-selling opportunities, such as through the recent cyberattack on competitor Change Healthcare, could benefit Waystar in the long term.
This aggregate rating is based on analysts' research of Waystar Holding Corp and is not a guaranteed prediction by Public.com or investment advice.
WAY Analyst Forecast & Price Prediction
Start investing in WAY
Order type
Buy in
Order amount
Est. shares
0 shares